SCHEMBL1157501

SCHEMBL1157501

CCOCCOCCOCC(N)N

nearest known ligand 0.41

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.32
THRB P10828 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28965774 1.00 ALDH1A1 (0.41) ALDH1A1TSHRHSD17B10THRB
SCHEMBL9229997 1.00 ALDH1A1 (0.41) ALDH1A1TSHRHSD17B10THRB
SCHEMBL1160884 0.97 ALDH1A1 (0.42) ALDH1A1TSHRHSD17B10THRB
Hydrochloric Acid SCHEMBL6464397 0.95 ALDH1A1 (0.41) ALDH1A1TSHRHSD17B10THRB
SCHEMBL1699179 0.87 HTT (0.36) ALDH1A1TSHRHSD17B10
SCHEMBL4422860 0.87 HTT (0.41) ALDH1A1TSHRHSD17B10
SCHEMBL4419652 0.85 HTT (0.44) ALDH1A1TSHR
SCHEMBL454517 0.83
SCHEMBL19304546 0.83
SCHEMBL8845606 0.80 TSHR (0.46) ALDH1A1TSHRHSD17B10THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4496840-B1 SURFACE ACTIVATION OF SILICONE HASKOLI ISLANDS (IS) 2026-02-04 EP claimed
US-20250215175-A1 SURFACE ACTIVATION OF SILICONE HASKOLI ISLANDS (IS) 2025-07-03 US claimed
EP-4496840-A1 SURFACE ACTIVATION OF SILICONE Haskoli Islands (IS) 2025-01-29 EP claimed
WO-2023181081-A1 SURFACE ACTIVATION OF SILICONE HASKOLI ISLANDS (IS) 2023-09-28 WO claimed
WO-2023144709-A1 PREPARATION AND APPLICATION OF POLYIMIDE INTERMEDIATES FOR ANTI-CORROSION COATING ON METAL SURFACES TATA STEEL LIMITED (IN) 2023-08-03 WO claimed
US-20200406347-A1 COMPOSITIONS COMPRISING EUTECTIC METAL ALLOY NANOPARTICLES XEROX CORPORATION (US) 2020-12-31 US claimed
US-20200038949-A1 COMPOSITIONS COMPRISING EUTECTIC METAL ALLOY NANOPARTICLES XEROX CORPORATION (US) 2020-02-06 US claimed
EP-3507335-A1 POLYMER COATINGS Commonwealth Scientific and Industrial Research Organisation (AU) 2019-07-10 EP claimed
WO-2018039721-A1 POLYMER COATINGS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2018-03-08 WO claimed
EP-3288520-A1 USE OF ACTIVE AGENTS DURING CHEMICAL TREATMENTS L'OREAL (FR) 2018-03-07 EP claimed
WO-2016179017-A1 USE OF ACTIVE AGENTS DURING CHEMICAL TREATMENTS L'OREAL (FR) 2016-11-10 WO claimed
WO-2013020005-A2 OXAZOLINE POLYMER COMPOSITIONS AND USE THEREOF ANP TECHNOLOGIES, INC. (US) 2013-02-07 WO claimed
EP-4496840-B1 SURFACE ACTIVATION OF SILICONE HASKOLI ISLANDS (IS) 2026-02-04 EP disclosed
US-20250215175-A1 SURFACE ACTIVATION OF SILICONE HASKOLI ISLANDS (IS) 2025-07-03 US disclosed
US-20250163006-A1 New Coolants, and Preparations Containing Same SYMRISE AG (DE) 2025-05-22 US disclosed
EP-3663366-B1 USE OF PHYSIOLOGICAL COOLING INGREDIENTS AND AGENTS CONTAINING SUCH ACTIVE INGREDIENTS SYMRISE AG (DE) 2025-01-08 EP disclosed
WO-1997031899-A1 SYNTHETIC DERIVATIVES OF RAPAMYCIN AS MULTIMERISING AGENTS FOR CHIMERIC PROTEINS WITH IMMUNOPHILIN DERIVED DOMAINS ARIAD GENE THERAPEUTICS, INC. (US) 1997-09-04 WO disclosed
EP-0776327-A1 NEW MULTIMERIZING AGENTS ARIAD GENE THERAPEUTICS, INC. (US) 1997-06-04 EP disclosed
WO-1996006097-A1 NEW MULTIMERIZING AGENTS ARIAD GENE THERAPEUTICS, INC. (US) 1996-02-29 WO disclosed
EP-0269832-A2 Impact-resistant dimensionnaly stable polyamide moulding compound BAYER AG (DE) 1988-06-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163006-A1 New Coolants, and Preparations Containing Same TTR, TAS2R5, TAS2R50 ALDH1A1 811/4885TSHR 2090/4885HSD17B10 1631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.